The International Prognostic Scoring System (IPSS), published in 1997, is used by many doctors to help assess the severity of a patient's myelodysplastic syndrome (MDS). Based on the IPSS score, the patient's history, and the physician's own personal observations, the physician will design a treatment plan to address the MDS.
| International Prognostic Scoring System | |
|---|---|
| Purpose | Assess severity of myelodysplastic syndrome |
Process edit
The IPSS uses three "prognostic indicators" to develop a "score" which may be useful in understanding how the MDS may progress:[citation needed]
- the proportion of blast cells in the bonemarrow
- the type of chromosomal changes, if any, in the marrow cells
- the presence of one or more low blood cell counts (cytopenias)
Each indicator is rated according to its severity and the ratings are combined into a "score".
Scores are sorted into one of four risk categories:[citation needed]
- low
- intermediate-1
- intermediate-2
- high
The two lower categories can be further described as the lower risk group while the two upper categories can be further described as the higher risk group.[1]
A revised IPSS, IPSS-R was published in 2012. IPSS-R is more refined in its prognostic precision and includes five instead of four prognostic groups.
References edit
- ^ "The International Prognostic Scoring System | The Leukemia & Lymphoma Society". www.lls.org. Archived from the original on 2012-02-07.